Skip to main content

Table 3 Values of BMI, body weight, fasting glucose levels and HbA1c in in patients with type 2 diabetes (T2DM patients) subdivided into carriers of the COMT Val108/158Met and DBH-1021C/T genotypes

From: The influence of dopamine-beta-hydroxylase and catechol O-methyltransferase gene polymorphism on the efficacy of insulin detemir therapy in patients with type 2 diabetes mellitus

  At baseline After 52-week treatment period
COMT Val108/158Met genotype (number of patients) AA (39) AG (101) GG (45) AA (39) AG (101) GG (45)
BMI (kg/m2) 29.41 (22.59–37.8) 30.02 (20.66–47.80) 30.04 (20.98–52.6) 29.28 (23.84–37.78) 30.10 (22.55–45.17) 29.39 (22.92–47.26)
Kruskal–Wallis ANOVA on Ranks H = 0.137; df = 2; p = 0.934 H = 0.067; df = 2; p = 0.967
Body weight (kg) 85.00 (63.00–106.00) 82.00 (54.00–127.00) 84.00 (59.00–128.00) 84.00 (64.00–108.00) 83.00 (55.00–120.00) 82.00 (59.00–115.00)
Kruskal–Wallis ANOVA on ranks H = 0.662; df = 2; p = 0.719 H = 0.167; df = 2; p = 0.920
Fasting glucose levels (mmol/L) 12.30 (7.00–18.90) 11.00 (5.20–19.70) 11.70 (8.20–21.30) 8.40 (4.40–17.70) 8.10 (4.60–15.90) 8.10 (5.40–14.50)
Kruskal–Wallis ANOVA on ranks H = 2.116; df = 2; p = 0.347 H = 0.397; df = 2; p = 0.820
HbA1c 8.4 (7.00–11.20) 8.4 (6.20–11.80) 8.5 (7.20–12.80) 7.7 (6.20–10.20) 7.6 (5.10–10.5) 8.00 (5.80–11.90)
Kruskal–Wallis ANOVA on ranks H = 2.684; df = 2; p = 0.261 H = 4.965; df = 2; p = 0.084
  At baseline After 52-week treatment period
DBH-1021C/T genotype (number of patients) CC (113) CT (64) TT (8) CC (113) CT (64) TT (8)
BMI (kg/m2) 29.88 (20.66–47.80) 30.04 (22.19–52.60) 34.26 (26.47–35.51) 30.10 (22.55–45.17) 29.40 (22.60–47.26) 30.86 (27.14–34.26)
Kruskal–Wallis ANOVA on ranks H = 1.426; df = 2; p = 0.490 H = 1.018; df = 2; p = 0.601
Body weight (kg) 82.00 (58.00–127.00) 84.50 (54.00–128.00) 89.00 (72.00–110.00) 82.00 (57.00–120.00) 83.50 (55.00–115.00) 87.00 (72.00–106.00)
Kruskal–Wallis ANOVA on ranks H = 1.279; df = 2; p = 0.527 H = 1.403; df = 2; p = 0.498
Fasting glucose levels 11.10 (5.20–20.10) 11.5 (7.10–21.30) 11.9 (9.10–12.80) 8.25 (5.20–15.90) 8.25 (4.40–17.70) 7.10 (6.20–11,10)
Kruskal–Wallis ANOVA on ranks H = 1.073; df = 2; p = 0.585 H = 0.373; df = 2; p = 0.830
HbA1c 8.50 (6.50–12.80) 8.40 (6.20–11.80) 8.65 (7.80–10.20) 7.70 (5.90–11.90) 7.8 (5.10–10.30) 7.7 (6.20–8.60)
Kruskal–Wallis ANOVA on ranks H = 0.612; df = 2; p = 0.736 H = 0.302; df = 2; p = 0.860
  1. * Data are presented as median and minimum and maximum
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us